Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : 2-Hydroxyflutamide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Nice & Green
Deal Size : $4.3 million
Deal Type : Financing
Details : Proceeds drawn by LIDDS under the convertible notes agreement will be used to further advance the project in clinical development, creating a solid foundation for new partnerships and license agreements for Liproca, based on the NanoZolid® technology.
Brand Name : Liproca
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 22, 2022
Lead Product(s) : 2-Hydroxyflutamide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Nice & Green
Deal Size : $4.3 million
Deal Type : Financing
NanoZolid®-formulated Docetaxel is Safe and Tolerable Showing Signs of Clinical Efficacy
Details : NZ-DTX-001 is intratumoural depot formulation of NanoZolid® in combination with docetaxel for treatment of solid tumors.
Brand Name : NZ-DTX
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 04, 2021
Prostate Cancer Study to Be Initiated at Uppsala University Hospital with Nano Zolid Technology®
Details : The study will assess intratumoral injections of NZ-DTX Depot, containing the cytotoxic agent docetaxel, in men with prostate cancer who are scheduled for prostatectomy.
Brand Name : NZ-DTX
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 16, 2021
Lead Product(s) : NZ-TLR9
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Pharmidea
Deal Size : Undisclosed
Deal Type : Collaboration
Lidds and Pharmidea Signs Manufacturing Agreement
Details : The collaboration enables LIDDS to expand the manufacturing of new product candidates, e.g. including biomolecules and cytostatics, in addition to the already existing collaboration with Recipharm for Liproca Depot.
Brand Name : NZ-TLR9
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
February 26, 2021
Lead Product(s) : NZ-TLR9
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Pharmidea
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : 2-Hydroxyflutamide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The study met both primary and secondary endpoints by confirming efficacy and safety with Liproca Depot given as intraprostatic injection in low- and intermediate risk prostate cancer patients.
Brand Name : Liproca Depot
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 04, 2021
Lead Product(s) : 2-Hydroxyflutamide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : NZ-TLR9
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LIDDS' NanoZolid-TLR9 Agonist Demonstrates Strong and Durable Preclinical Anti-Tumoral Effect
Details : The results indicate that NanoZolid technology®, with controlled & sustained drug release, can be used to treat deep lying cancer tumors, which are not suitable to be treated with standard TLR9 due to the necessity of weekly injections.
Brand Name : NZ-TLR9
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
October 26, 2020
Lead Product(s) : NZ-TLR9
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : 2-Hydroxyflutamide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LIDDS Announces Data on Liproca Depot from Open Label Extension Study
Details : In patients who received a second Liproca® Depot injection (6 of 12), at 2 months post treatment, PSA levels were in average reduced by 28 %.
Brand Name : Liproca Depot
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 30, 2020
Lead Product(s) : 2-Hydroxyflutamide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : 2-Hydroxyflutamide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Liproca Phase II b Study Results Indicate Cancer Control
Details : Final data from the LPC-004 study confirms Liproca® Depot’s potential as a safe and effective anti-androgen treatment for prostate cancer patients that currently are not treated but kept under ‘Active Surveillance’.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 19, 2020
Lead Product(s) : 2-Hydroxyflutamide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Additional patients treated in LIDDS clinical study NZ-DTX-001
Details : Dose escalation in the Phase I study NZ-DTX is proceeding according to the protocol, with additional patients being treated at a higher dose level of NZ-DTX.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 01, 2020
Lead Product(s) : NZ-TLR9
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LIDDS announces positive preclinical data for NanoZolid®-TLR9 agonist project
Details : Clinical data have shown that intratumoral delivery of TLR9 agonists can effectively treat solid cancers.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
March 25, 2020
Lead Product(s) : NZ-TLR9
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?